First Tracks Biotherapeutics
TRAX----
First Tracks Biotherapeutics (TRAX)
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
First Tracks Biotherapeutics Analyst Rating
View MoreForecast & Rating
Jul 21, 2026Price forecast
$43.8823.59%
Forecast & RatingStrong buy
8analysts
- Strong buy62.50%
- Buy37.50%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · 1 day ago, 07:06 AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Global Report · Jul 14 at 06:47 AM
Capital Moves Take Center Stage: From AutoZone's Massive Buyback to Biotech Debuts
- benzinga_article · Jul 10 at 11:34 AM
First Tracks Biotherapeutics shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $30 to $44.
- rttnews · Jul 10 at 07:21 AM
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT
- benzinga_article · Jul 9 at 12:05 PM
12 Health Care Stocks Moving In Thursday's Intraday Session
- Tip Ranks · Jul 8 at 08:25 AM
Buy Rating on First Tracks (TRAX) Driven by Strengthening IL-15/CD122 Pathway Validation and Upcoming ANB033 Clinical Catalysts in Celiac Disease and Vitiligo
